Immunization of mice by Hollow Mesoporous Silica Nanoparticles as carriers of Porcine Circovirus Type 2 ORF2 Protein
暂无分享,去创建一个
Huizhi Guo | Zai-xin Liu | Shiqi Sun | H. Yin | Xiang-tao Liu | De-hui Sun | Yan-quan Wei | Jian-Xiong Luo | Xiaoyun Feng | Yan-quan Wei
[1] Huizhi Guo,et al. Immunization of mice by Hollow Mesoporous Silica Nanoparticles as carriers of Porcine Circovirus Type 2 ORF2 Protein , 2012, Virology Journal.
[2] Linlin Li,et al. Mesoporous Silica Nanoparticles: Synthesis, Biocompatibility and Drug Delivery , 2012, Advanced materials.
[3] Yaping Li,et al. Controlled intracellular release of doxorubicin in multidrug-resistant cancer cells by tuning the shell-pore sizes of mesoporous silica nanoparticles. , 2011, ACS nano.
[4] M. Haessig,et al. Vaccination of Dams Increases Antibody Titer and Improves Growth Parameters in Finisher Pigs Subclinically Infected with Porcine Circovirus Type 2 , 2011, Clinical and Vaccine Immunology.
[5] Dehui Sun,et al. Hollow mesoporous silica nanoparticles for intracellular delivery of fluorescent dye , 2011, Chemistry Central journal.
[6] J. Segalés,et al. Recent advances in the epidemiology, diagnosis and control of diseases caused by porcine circovirus type 2. , 2011, Veterinary journal.
[7] K. Podgórska,et al. Efficacy of different protocols of vaccination against porcine circovirus type 2 (PCV2) in a farm affected by postweaning multisystemic wasting syndrome (PMWS). , 2010, Comparative immunology, microbiology and infectious diseases.
[8] Huizhi Guo,et al. Development and validation of an ELISA using a protein encoded by ORF2 antigenic domain of porcine circovirus type 2 , 2010, Virology Journal.
[9] Yu Chen,et al. Core/shell structured hollow mesoporous nanocapsules: a potential platform for simultaneous cell imaging and anticancer drug delivery. , 2010, ACS nano.
[10] T. Opriessnig,et al. Comparison of the effectiveness of passive (dam) versus active (piglet) immunization against porcine circovirus type 2 (PCV2) and impact of passively derived PCV2 vaccine-induced immunity on vaccination. , 2010, Veterinary microbiology.
[11] A. Mankertz,et al. Porcine circoviruses--small but powerful. , 2009, Virus research.
[12] Yong-Min Huh,et al. Hollow silica nanocontainers as drug delivery vehicles. , 2008, Langmuir : the ACS journal of surfaces and colloids.
[13] P. Jiang,et al. Protection of pigs against post-weaning multisystemic wasting syndrome by a recombinant adenovirus expressing the capsid protein of porcine circovirus type 2. , 2007, Veterinary microbiology.
[14] Hirokazu Miyoshi,et al. Encapsulated ultrasound microbubbles: therapeutic application in drug/gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.
[15] J. Kwang,et al. The ORF3 Protein of Porcine Circovirus Type 2 Is Involved in Viral Pathogenesis In Vivo , 2006, Journal of Virology.
[16] Yufang Zhu,et al. Stimuli-responsive controlled drug release from a hollow mesoporous silica sphere/polyelectrolyte multilayer core-shell structure. , 2005, Angewandte Chemie.
[17] Jiyong Zhou,et al. In vitro expression, monoclonal antibody and bioactivity for capsid protein of porcine circovirus type II without nuclear localization signal. , 2005, Journal of biotechnology.
[18] A. C. Hunter,et al. Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[19] P. Lekcharoensuk,et al. Epitope Mapping of the Major Capsid Protein of Type 2 Porcine Circovirus (PCV2) by Using Chimeric PCV1 and PCV2 , 2004, Journal of Virology.
[20] A. Bøtner,et al. Immunisation against PCV2 structural protein by DNA vaccination of mice. , 2004, Vaccine.
[21] E. Albina,et al. Protection of swine against post-weaning multisystemic wasting syndrome (PMWS) by porcine circovirus type 2 (PCV2) proteins. , 2003, Vaccine.
[22] M. Kiupel,et al. Viral Replication and Lesions in BALB/c Mice Experimentally Inoculated with Porcine Circovirus Isolated from a Pig with Postweaning Multisystemic Wasting Disease , 2001, Veterinary pathology.
[23] J. Ellis,et al. Production, characterisation and applications of monoclonal antibodies to porcine circovirus 2 , 2001, Archives of Virology.
[24] E. Albina,et al. Identification of an immunorelevant ORF2 epitope from porcine circovirus type 2 as a serological marker for experimental and natural infection , 2001, Archives of Virology.
[25] J. Hemmen,et al. Cytokine-modulated regulation of helper T cell populations. , 2000, Journal of theoretical biology.
[26] S. Sorden,et al. Open reading frame 2 of porcine circovirus type 2 encodes a major capsid protein. , 2000, The Journal of general virology.
[27] A. Hill,et al. Vaccines against intracellular infections requiring cellular immunity , 2000, Nature.
[28] E. Albina,et al. Differential recognition of ORF2 protein from type 1 and type 2 porcine circoviruses and identification of immunorelevant epitopes. , 2000, The Journal of general virology.
[29] P. Kalinski,et al. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. , 1999, Immunology today.
[30] Katarina Wolf,et al. Identification of a protein essential for replication of porcine circovirus. , 1998, The Journal of general virology.
[31] S. Constant,et al. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. , 1997, Annual review of immunology.
[32] Kenneth M. Murphy,et al. Functional diversity of helper T lymphocytes , 1996, Nature.
[33] P. Galan,et al. Lymphocyte subpopulations in the thymus, lymph nodes and spleen of iron-deficient and rehabilitated mice. , 1991, The Journal of nutrition.
[34] T. Mosmann,et al. Functional diversity of T lymphocytes due to secretion of different cytokine patterns , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[35] L. Wang,et al. Virology Journal , 1966, Nature.